| Indikation | Kurzbezeichnung | EudraCT-Nr. | Phase | Titel | Studie aktiv? Ja/nein |
|---|---|---|---|---|---|
| ALL | GMALL-MOLACT1-BLINA Blast Successor Trial | 2015-000733-76 | II | A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BITE ® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial) | ja |
| ALL | GMALL 08/2013 | 2013-003466-13 | IV | Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie | ja |
| ALL | ALL-Register | n/a | n/a | GMALL ALL-Register | ja |
| AML | Shape | 2019-004536-37 | II | Treatment of MDS / AML patiens with an impending Hematological relapse with Azaci-tidine alone or in combination with PEvonedistat – a randomized phase 2 trial | ja |
| AML | ETAL3-ASAP | 2014-003124-44 | III | Evaluation of the impact of remission induction chemotherapy prior to allogeneic stemm cell transplantation in relapsed and poor-response patients with AML | ja |
| AML | CPKC412A2301 | 2006-006852-37 | III | A phase III randomized, double blind study of induction (daunorubicin/cytarabine) and con_solidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diag_nosed patients <60 years of age with FLT3 mutated Acute Myeloid Leukemia | ja |
| AML | BLAST | 2014-002702-21 | II | A double-blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to consolidation therapy in AML patients | ja |
| AML | ARO-013 | 2017-001600-29 | III | Phase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crnolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia | ja |
| AML | AML-Register | n/a | n/a | AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) | ja |
| AML | AG120-C-009 | 2016-004907-30 | III | A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy | ja |
| AML | 2DAUNO (DaunoDouble) | 2013-003191-12 | III | Randomized comparison between two dose levels of daunorobicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 60 years | ja |
| AML / MDS | PALOMA | 2018-002430-21 | II | Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogeneic cell transplantation in patients with higher risk MDS and oligoblastic AML - the PALOMA study | ja |
| Anämie | MOM-M281-006 | 2019-000720-17 | II/III | Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study with a Long-term Open-label Extension | ja |
| Anämie | EMAA 9345 | 2014-000174-19 | II/III | Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A | ja |
| Anämie | CSEG101A2301 | 2017-001746-10 | III | A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus Placebo, wth or without Hydroxyurea/Hydroxycabamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crisis (STAND) | ja |
| Anämie | C-935788-057 | 2018-004774-97 | III | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fastamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ja |
| APL | NAPOLEON-Register | n/a | n/a | National Acute Promyelocytic Leukemia (APL) Observational Study Napoleon-Registry of the German AML-Intergroup | ja |
| APL | APOLLO | 2015-001151-68 | III | A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia | ja |
| CAD | PDY16370 BIVV020 | 2019-001844-22 | 1b | A multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin disease | ja |
| CLL | CLL-RT1 | 2018-002492-17 | II | A Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG) | ja |
| CLL | CLL-Register | n/a | n/a | Registry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation | ja |
| NHL | Alternative C | 2018-004038-13 | II | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden | ja |
| CLL | ACP-196 D8220C00008 (Astra Zeneca) Assure | III b | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | ja | |
| CML | PONS | 2016-000618-30 | II | Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatment | ja |
| CML | Ponderosa | IV | Beobachtungsstudie mit Patienten mit CML in allen Phasen, die mit Ponatinib (Iclusig ®) in jeglicher Dosierung behandelt werden | ja | |
| CML | NAUT CAMN107ADE22T | 2015-004998-33 | n/a | Multicenter prospective trial after first unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd time | ja |
| CML | Fascination | 2018-002256-33 | II | Frontline Asciminib combination in chronic phase CML | ja |
| CML | ENDURE CML-IX | 2016-001030-94 | II | Randomisierte Phase II Studie zur Untersuchung der Sicherheit und Effektivität einer Therapie mit pegyliertem Prolin-Interferon alpha 2b (AOP2014) zur Erhaltung einer tiefen molekularen Remission bei Patienten mit chronischer myeloischer Leukämie – eine randomisierte, multizentrische Phase-II-Studie mit anschließender Nachbeobachtungsphase außerhalb der Studie | ja |
| CML | Dastop-2 MED3_201701 | 2016-004106-34 | II | Persistance of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: a multicenter prospective trail | ja |
| CML | DasaHIT | 2015-003502-16 | III | Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative ABL-kinase inhibitors (≥2nd line) | ja |
| CML | CAMN107ADE20 NILO-deep-R | 2015-000968-34 | IV | A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300 mg BID | ja |
| HD | HD21 | 2014-005130-55 | III | Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD | ja |
| ITP | ARGX-113-1803 | 2019-002100-41 | III | A Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia | ja |
| ITP | ARGX-113-1801 | 2019-002100-41 | III | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia | ja |
| MCL | PCYC-1143-CA | 2017-000129-12 | III | Phase 3 Study of Ibrutnib in Combination with Venetoklax in Subjects with Mantle Cell Lymphoma | ja |
| MCL | INCB 50465-205 CITADEL-205 | 2017-003148-19 | II | A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3K_ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | ja |
| MM | MP0250-CP201 "MiRRoR" | 2016-002771-10 | II | A Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myeloma | ja |
| MM | 54767414MMY2065LYNX | 2018-004185-34 | II | A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment | ja |
| MM | GMMG-CONCEPT | 2016-000432-17 | II | Eine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms | ja |
| MPN | SRA-MMB-301 | 2019-000583-18 | III | A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy | ja |
| MPN | SAL-MPN-Register | n/a | n/a | SAL-MPN-Register und Biomaterieldatenbank der Studienallianz Leukämie (SAL) | ja |
| MPN | MMM 02 study CTC12729 | 2014-005210-28 | II | Ruxolitinib versus allogenic stem cell transplantation für patients with myelofibrosis according to donor availability: A prospective phase II (MMM 02study) | ja |
| MPN | IMG-7289-CTP-201 | 2019-003659-13 | II | A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia | ja |
| MPN | CINC424BDE12 PaVe-NIS | n/a | n/a | PaVe - Eine prospektive, nicht-interventionelle Studie zur JAKAVI®-Behandlung von Patienten mit Polycythaemia vera | ja |
| MPN | Besremi-PASS EUPAS29462 | n/a | II b | A Prospective, Multicentre, Non-interventional, Observational, Post-authorisation Safety Study of Ropeginterferon alfa-2b in Polycythaemia Vera Patients | ja |
| MZoL | OLYMP-1 | 2017-003149-56 | II | Phase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphoma | ja |
| MZoL | Marginalzonenlymphom-Register | n/a | n/a | Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen | ja |
| MZoL | INCB 50465-204 CITADEL-204 | 2017-000970-12 | II | A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3K_ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphome With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204) | ja |
| NHL agg. | TIGER-Studie CTL-019 | 2019-002930-35 | II | Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Ag-gressive B-cell Non-Hodgkin Lymphoma | ja |
| NHL agg. | SGN35-014 "ECHELON-2" | 2012-002751-42 | III | A randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30_positive mature T-cell lymphomas | ja |
| NHL agg. | Ro-CHOP | 2012-001580-68 | III | Phase 3 multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma | ja |
| NHL agg. | ImbruVeRCHOP | 2015-003429-32 | n/a | Ibrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2 | ja |
| NHL agg. | MB-CART2019.1 M-2018-331 | 2018-001253-27 | I/II | A Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL | ja |
| NHL agg. | DSHNHL 2015-1 NIVEAU | 2016-002272-27 | n/a | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease | ja |
| NHL ind. | ML29941 GAZAI | 2016-002059-89 | I/ II | Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro | ja |
| NHL ind. | HOVON 110 FL ReBeL Study | 2011-000097-56 | I/II | A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. | ja |
| NHL ind. | GABe 2016 | 2016-000755-27 | III | First line therapy of advanced stage follicular lymphoma in patients not eligible for standard immunochemotherapy. Prospective randomized comparison of single agent GA101 versus GA101 plus bendamustine followed by GA101 in medically non-fit patients | ja |
| PNH | CLNP023X2201 | 2017-000888-33 | III | An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in Patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis | ja |
| PNH | BP39144 "Composer" | 2016-002128-10 | I/II | An adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) | ja |
| PNH | BO42162 Commodore 2 naive | 2019-004931-21 | III | A phase 3, randomized, open label, active controlles, multicenter study, evaluating the efficacy and safety of Crovalimab versus Eculizumab in Adult and andolescent patients with paroxismal nocturnal Hemoglobinuria not previously treated with complement inhibitors. | ja |
| PNH | APL2-307 | 2019-001106-23 | III | An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). | ja |
| ZNS | MARTA | 2016-001628-72 | II | Multizentrische Phase II-Studie zur altersadaptierten Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren Patienten > 65 Jahren mit primär zerebralem Lymphom | ja |
| CLL | CLL 17 | 2019-003854-99 | III | A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) | ja |
| PNH | BO42161 Commodore 1 switch | 2019-004931-21 | III | A Phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients with PNH currently treated with complement inhibitors | ja |
| MPN | M16-191 | III | A Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib Alone in Subjects with Myelofibrosis, Transform-1 | ja | |
| PNH | CLNP023C12302 | 2019-004665-40 | III | A randomized, multicenter, active-comparator controlled, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibody | ja |
| NHL agg. | Coach | n/a | n/a | Comprehensive Analysis of Immune Checkpoint Inhibition in Relapsed Hodgkin Lymphoma | ja |
| AL-Amyloidose | CAEL301-301 | 2019_004254_28 | III | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis | ja |
| AL-Amyloidose | CAEL301-302 | 2020-000713-32 | III | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis | ja |
| Waiha | ANX-wAIHA-01 | n/a | n/a | “A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “ | ja |
| AML | TUD-MOSAIC-075 | 2019-003863-23 | II | Multizentrische Studie mit Phase-I-Teil im 3+3 Studiendesign (MODULE) und einem randomisiert kontrollierten doppelblinden (MAGNOLIA) und randomisierten unverblindeten (MAGMA) Phase-II-Teil | ja |
| CAD | LTS16637 | 2019-004423-21 | 1b | An open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with BIVV020 | ja |
| AML | Relax | 2018-003025-28 | I / II | Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (RELAX) | ja |
©2020
Klinik für Hämatologie und Stammzelltransplantation
Menü